RxDoctor Payments Data

Shane Seipel, MD

Cornea and External Diseases Specialist · Fairview Park, OHNPI 1780117945

Payments from drug & device makers

$904in general payments, 2019–2025

Across 31 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$417
  • Sun Pharmaceutical Industries Inc.$127
  • Bausch & Lomb Americas Inc.$64
  • Tarsus Pharmaceuticals, Inc.$64
  • Dompe US, Inc.$52
  • Ocular Therapeutix, Inc.$46
  • plus $133 from 5 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$253,975
Medicare patients
652
Services billed
2,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$21,112
Prednisolone Acetate312$12,743
ProlensaBromfenac Sodium37$11,354
Bromfenac Sodium57$10,737
LumiganBimatoprost13$9,497
Cyclosporine17$7,960
MoxifloxacinMoxifloxacin Hcl264$5,853
Latanoprost441$4,845
Travoprost23$3,802
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$2,448
Timolol MaleateTimolol Maleate/Pf11$2,310
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$1,481
Brimonidine Tartrate103$1,004
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha75$936
Timolol Maleate61$768

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$45$30,60928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Ohioon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Fairview Park

Where these figures come from

Is this you, or does something look wrong? →